StonvexLoading…
StonvexStonvexStonvexCore line items from ACCS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $22.62M | $23.06M | $24.52M | $23.51M |
Operating Income | $-1.87M | $-16.32M | $-2.74M | $2.67M |
Net Income | $4.29M | $-10.79M | $766.00K | $1.93M |
EPS (Diluted) | $1.11 | $-2.82 | $0.20 | $0.52 |
Total Assets | $41.99M | $50.64M | $65.15M | $66.33M |
Total Liabilities | $11.65M | $25.41M | $29.73M | $33.10M |
Cash & Equivalents | $3.02M | $4.10M | $5.71M | $4.83M |
Free Cash Flow OCF − CapEx | $538.00K | $3.14M | $3.04M | $3.95M |
Shares Outstanding | 3.85M | 3.84M | 3.82M | 3.79M |